Zack’s just increased its price target on this little-known biotech gem.

With earnings blowing past expectations and a $9.25 Zacks price target, this biotech company could be ready for BLUE-SKY growth ahead. ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from Huge Alerts Two massive multi-billion-dollar markets for its regenerative therapies position this company as one of the most promising up-and-coming medtech stocks on Wall Street! The medtech arena is not the easiest to navigate given how many kinds of companies are in it. It’s all about finding emerging players like this underfollowed company which has astronomical growth potential. Zack’s Small Cap Research recently increased its price target on the stock to $9.25! This notable research firm sees the VALUE! According to Zack’s report, the company is “still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future. The vision management has for the company’s product and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand.” These optimistic comments and bullish price target came shortly after the company reported explosive Q3 earnings that beat expectations. See why this little-known medtech company could see a major upside in the near future!

This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of MarketBeat. Why did I receive this email?     This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2024 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: It's the hottest options trade ever...